Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Poster presentation

The crucial role of osteocyte-derived RANKL in bone homeostasis

Authors: Tomoki Nakashima, Mikihito Hayashi, Hiroshi Takayanagi

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

Receptor activator of NF-κB ligand (RANKL; also known as TNFSF11), a TNF family molecule, and its receptor RANK (TNFRSF11A) are key regulators of osteoclast differentiation and function. Aberrant expression of RANKL explains why autoimmune diseases, cancers, leukemia and periodontal disease result in systemic and local bone loss. In particular, RANKL is the pathogenic factor that cause bone and cartilage destruction in arthritis. Inhibition of RANKL function by the natural decoy receptor osteoprotegerin (OPG; also known as TNFRSF11B) or anti-RANKL antibody prevents bone loss in postmenopausal osteoporosis, cancer metastases and arthritis. RANKL also regulates T cell/dendritic cell communications, dendritic cell survival and lymph node organogenesis. Intriguingly, RANKL and RANK play an essential role in the maturation of mammary glands in pregnancy and lactation. Bone homeostasis depends on the coordination of osteoclastic bone resorption and osteoblastic bone formation. We reported that RANKL induces osteoclast differentiation through activating a transcriptional programme mediated by the master transcription factor nuclear factor of activated T cells (NFAT) c1. Although it is well accepted that the RANKL-NFATc1 pathway is crucially important for osteoclast differentiation, little is known about the major cellular source of RANKL in the skeletal tissue. RANKL has been postulated to be mainly expressed by osteoblasts and bone marrow stromal cells. However, here we show that osteocytes embedded within the bone matrix are the critical source of RANKL in bone remodeling. Osteocytes, the most abundant cell type in bone, are thought to orchestrate bone homeostasis by regulating both osteoclastic bone resorption and osteoblastic bone formation, but in vivo evidence and the molecular basis for the regulation has not been sufficiently demonstrated. Using a newly established method for the isolation of high-purity dentin matrix protein 1-positive osteocytes from bone, we have found that osteocytes express a much higher amount of RANKL and have a much greater capacity to support osteoclast formation than osteoblasts and bone marrow stromal cells. The crucial role of RANKL expressed by osteocytes was validated by the severe osteopetrotic phenotype observed in mice lacking RANKL specifically in osteocytes. Thus, we provide in vivo evidence for the key role of osteocyte-derived RANKL in bone homeostasis, establishing a molecular basis for osteocyte regulation of bone resorption. …
Metadata
Title
The crucial role of osteocyte-derived RANKL in bone homeostasis
Authors
Tomoki Nakashima
Mikihito Hayashi
Hiroshi Takayanagi
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3654

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.